We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The agency noted that roughly 88 percent of customer complaints were related to the bed’s adjustable base, but the firm failed to request a corrective action by the supplier. Read More
Numerous bugs were reported related to IT Synergistics’ LifeTec Elite version 1 and 2 blood establishment computer software but were not documented as complaints and weren’t investigated, according to a 483 the firm received following a March 5-6, and June 23 FDA inspection of its Flowood, Mississippi facility. Read More
Failure to submit a field report to the FDA, and failure to submit medical device reports were just two of the 13 quality lapses that dogged specification developer Craftmatic Industries found during an FDA inspection at its Pompano Beach, Florida facility. Read More
The FDA cited many reportable events that could be linked to the decontamination system and said the company should have reported them to the agency. Read More
The FDA found orthopedic devicemaker BioSculptor’s production processes were “not developed, controlled and monitored to ensure that a device conforms to its specifications,” according to a 483 the firm received following an FDA inspection at its Hialeah, Florida facility. Read More
Inadequate design validation procedures and a lack of environmental controls were among the quality system lapses observed during an FDA inspection of Pegasus Research’s Santa Ana, California facility. Read More
Inadequate corrective and preventive action procedures and failure to implement written medical device reporting (MDR) procedures landed Pan Medical a 483 following an inspection at the firm’s Largo, Florida facility. Read More
The FDA cited six devicemakers for problems found during inspections of their facilities, including inadequate validations, medical device reporting and investigations into complaints. Read More
The design risk analysis for the firm’s infrared light therapy devices didn’t include an evaluation of all hazards that were “reasonably known,” the agency said. Read More
The FDA found Anodyne Therapy’s validation and risk analyses were inadequate, and reports of radiation were not sent to the FDA, according to a 483 the firm received follow an agency inspection of its Oldsmar, Florida facility. Read More
Devicemaker Genicon failed to provide adequate resources for quality control operations to ensure that devices were designed and produced according to FDA regulations, according to a 15-item Form 483 the firm received following an inspection of its Winter Park, Florida facility. Read More
Failure to validate the design of its Specboard, which is used to localize suspect breast lesions during surgery, was among the quality system lapses the FDA observed during an inspection of Macbrud’s Miami, Florida facility. Read More